News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
CSL Limited Plans A$900 (US$815) Million Share Buyback After Net Profit Slips
August 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- SYDNEY—CSL Ltd. said its full-year net profit fell 8% and the company unveiled a 900 million Australian dollar (US$815 million) share buyback.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Asia
Australia
MORE ON THIS TOPIC
Layoff Tracker
Prothena Downsizes by 63% in Aftermath of AL Amyloidosis Failure
June 23, 2025
·
145 min read
·
BioSpace Editorial Staff
Government
FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’
June 20, 2025
·
2 min read
·
Tristan Manalac
Business
Navigating Funding Freezes and AI Frontiers
June 20, 2025
·
1 min read
·
Lori Ellis
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
·
2 min read
·
Tristan Manalac
